The nation's bioscience industry continues to grow as states and regions vie to attract high-wage jobs, according to a study released on June 18, 2008, by Battelle (Columbus, OH) and the Biotechnology Industry Organization (BIO, Washington, DC).
The nation's bioscience industry continues to grow as states and regions vie to attract high-wage jobs, according to a study released on June 18, 2008, by Battelle (Columbus, OH) and the Biotechnology Industry Organization (BIO, Washington, DC).
The study, “Technology, Talent and Capital: State Bioscience Initiatives 2008,” presents data on national, state, and metropolitan bioscience employment and growth trends during 2001 to 2006. The study also examines a series of additional key performance metrics and describes state policies and programs designed to accelerate the growth of the biosciences. The report has been produced from the most current and comparable annual data available.
Total US employment in the biosciences reached 1.3 million in 2006, up from 1.2 million in 2004, led by strong growth in the research, testing, and medical laboratory subsector, which experienced a 17.8% increase in employment and a 32.7% increase in establishments between 2001 and 2006. Indirect and induced employment from the bioscience industry totals an additional 6.2 million jobs spread throughout the remainder of the economy.
Together, these direct, indirect, and induced jobs account for a total employment impact of 7.5 million jobs.
Following are some of the findings in the report:
In addition to employment, the report examines other indicators of the robustness of a state’s bioscience industry, including the level of bioscience R&D funding, venture capital investment, and patents. The highlights of additional key indicators include:
The study and individual profiles of the 50 states and Puerto Rico are available on the BIO website at http://www.bio.org/local/battelle2008.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.